Chongqing Zhifei Biological Products Co., Ltd.: history, ownership, mission, how it works & makes money

From its 2002 founding to its September 2010 listing on ChiNext under stock code 300122, Chongqing Zhifei Biological Products Co., Ltd. has grown into a leading Chinese vaccine maker with a broad product mix - including the Recombinant Novel Coronavirus Vaccine (CHO Cell), Recombinant Mycobacterium Tuberculosis Fusion Protein (Ekear®) and Haemophilus influenzae type b vaccine (XiFeiBei®) - and exclusive China distribution rights for Merck's HPV4 (Gardasil), HPV9 (Gardasil 9) and Pneumovax 23; by H1 2021 Zhifei reported operating income of RMB 13.2 billion, backed then by a registered capital of RMB 1.6 billion and total assets of RMB 23.9 billion, and it now employs 7,220 people as of December 31, 2024 (a 10.31% year-on-year increase), operating five wholly-owned subsidiaries plus a joint-stock subsidiary with Beijing Zhifei Lvzhu and Anhui Zhifei Longcom recognized as national high-tech enterprises; the firm combines two R&D bases and a central R&D center with a national cold-chain and a service network covering over 30,000 vaccination points in more than 300 cities, monetizing through direct sales of proprietary vaccines and distribution agreements while confronting recent revenue declines in 2024 and Q1 2025 and prioritizing inventory reduction and receivable recovery to shore up cash flow.

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ): Intro

• Founded: 2002
• Listing: Shenzhen Stock Exchange (ChiNext), Sep 2010 - stock code 300122
• Employees (H1 2021): ~4,500
• Registered capital: RMB 1.6 billion
• Total assets (H1 2021): RMB 23.9 billion
• Operating income (H1 2021): RMB 13.2 billion

• Five wholly-owned subsidiaries and one joint-stock subsidiary.
• Notable subsidiaries recognized as national high-tech enterprises:
  • Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd.
  • Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.

• Recombinant Novel Coronavirus Vaccine (CHO Cell) - one of the company's flagship COVID-19 vaccine candidates/products.
• Recombinant Mycobacterium Tuberculosis Fusion Protein (Ekear®) - TB vaccine candidate/product.
• Haemophilus Influenzae Type b Vaccine (XiFeiBei®) - pediatric vaccine product.
• Exclusive distributor in China for Merck Sharp & Dohme's vaccines, including:
  • HPV4 (Gardasil)
  • HPV9 (Gardasil 9)
  • 23-valent Pneumococcal polysaccharide vaccine (Pneumovax 23)

• R&D: In-house vaccine research leveraging recombinant protein and CHO-cell platforms for accelerated antigen production and scale-up.
• Manufacturing: Owns multiple GMP-compliant production facilities via subsidiaries; capacity scaled to meet domestic immunization and commercial demand.
• Regulatory: Engages with China's NMPA for clinical trials, approvals, and emergency use pathways (notably for COVID-19 products).
• Commercialization & distribution: Direct sales, hospital and clinic channels, and exclusive distribution agreements (e.g., MSD product lines) to broaden market access.

• Vaccine product sales: Core revenue from proprietary vaccines (e.g., XiFeiBei®, Ekear®, COVID-19 vaccine) sold to public immunization programs, private clinics, and hospitals.
• Exclusive distribution royalties/markup: Income from distributing international vaccines (Gardasil, Gardasil 9, Pneumovax 23) in China.
• R&D partnerships & licensing: Co-development, technology transfer and licensing deals with domestic and international partners.
• Government procurement and programs: Significant revenue via public tenders and inclusion in immunization lists boosts volume and predictable demand.

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ): History

• Stock ticker: 300122.SZ (Shenzhen Stock Exchange)
• Registered capital: RMB 1.6 billion
• Total assets (H1 2021): RMB 23.9 billion
• Employees (Dec 31, 2024): 7,220 (up 10.31% year-over-year)

• Subsidiary structure: five wholly‑owned subsidiaries and one joint‑stock subsidiary
• Notable subsidiaries:
  • Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd.
  • Anhui Zhifei Longcom Biopharmaceutical Co., Ltd.
• Ownership: publicly traded with a diverse shareholder base; financial and stock performance published for investor transparency

• R&D: invests in vaccine discovery and clinical development to create proprietary vaccine candidates and immune products.
• Manufacturing: GMP-certified production facilities produce vaccines (including pediatric and adult vaccines) and biologics for domestic and select export markets.
• Commercialization: sales to hospitals, CDC procurement channels, public immunization programs and private markets; recurring revenue from established vaccines and milestone/license income from collaborations.
• Revenue drivers: product sales (core), government procurement contracts, licensing/partnerships and occasional one-time technology transfer or milestone payments.

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ): Ownership Structure

• Mission: Enhance public health through preventive vaccines and broadened immunization coverage.
• Core values: Innovation in vaccine R&D, strict quality control, and commitment to social welfare.
• Philosophy: 'Social benefits go before corporate profits'-guiding corporate decisions and community efforts.

• Primary revenue drivers: commercial vaccine sales to domestic immunization programs and private-market vaccinations.
• Operating model highlights: in-house R&D and manufacturing capacity to support scale-up and supply consistency.
• Social initiatives: targeted donations, public-health collaborations, and educational support for rural communities.

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ): Mission and Values

• Integrated value chain: Zhifei integrates research & development, production, marketing, distribution and import/export to deliver vaccine products from lab to patient.
• R&D footprint: The company operates two R&D bases plus a central R&D center dedicated to human vaccine discovery, process development, quality control and clinical development.
• Cold chain and logistics: A comprehensive cold chain system meets national GSP requirements to ensure safe storage and transport of temperature‑sensitive biologics.
• Service network scale: Zhifei's service network covers over 30,000 vaccination points across more than 300 cities in China, supporting large‑scale immunization campaigns and routine vaccination.
• Global partnerships: Collaborations with international partners (notably Merck Sharp & Dohme) enable in‑country distribution and commercialization of vaccines such as HPV4 (Gardasil) and HPV9 (Gardasil 9).
• Commercial model: The company follows a "dual‑wheel" R&D + Marketing pattern-advancing pipeline programs in-house while building marketing, channel and public health relationships to accelerate commercialization.

• Product sales: Core revenue comes from marketed vaccines (routine and optional immunizations), with higher margins typically on proprietary vaccines versus contract manufacturing.
• Licensing & distribution: Income from partner product distribution (e.g., HPV vaccines) and licensing agreements complements direct product sales.
• Public procurement: Participation in provincial and national immunization programs and bidding processes drives volume sales for routine vaccines.
• Export & import operations: Cross‑border trade and importation of partner products (and selected exports) add revenue diversification.

• From lab to clinic: In‑house R&D advances candidates through preclinical and clinical stages using central R&D capabilities; successful candidates move to scale‑up at company manufacturing sites and then into the nationwide distribution network.
• Cold chain delivery: Finished vaccine lots are stored and transported under controlled temperature conditions, verified against GSP checkpoints before release to vaccination points.
• Market access: Marketing teams coordinate with provincial CDCs, hospital networks and private immunization clinics to secure procurement contracts and maintain >30,000 vaccination points.

• End‑to‑end control of product lifecycle-from R&D through cold chain distribution-reducing external dependency for critical steps.
• Large service network enabling scale and rapid roll‑out for new launches and public health campaigns.
• International collaborations that bring globally‑established vaccines to the Chinese market, complementing Zhifei's proprietary pipeline.

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ): How It Works

• Primary revenue from proprietary vaccines-most notably the Recombinant Novel Coronavirus Vaccine (CHO Cell) and the Ekear® series.
• Additional income from distribution agreements for international vaccines (e.g., Merck Sharp & Dohme HPV vaccines).
• Mixed sales channels: direct sales to hospitals, CDCs and public immunization programs plus commercial distribution partners and export channels.
• Operational focus on cash collection and inventory reduction to mitigate working‑capital and liability pressures after recent market headwinds.

• Revenue drivers: volume and pricing of in‑house vaccines; margins and volume from distributed international vaccines; government and institutional procurement cycles.
• Risk factors affecting cash flow: inventory buildup, slow receivables, and market demand fluctuations (contributed to 2024-Q1 2025 revenue declines).
• Management levers: shift sales mix toward stable institutional contracts, cut promotional spend, expedite collections and dispose excess inventory.

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ): How It Makes Money

• Core revenue streams: commercial vaccine sales to public immunization programs, private-pay vaccines (e.g., HPV, meningococcal), and bulk/contract manufacturing.
• Ancillary revenue: technology licensing, reagent and diagnostic product sales, and limited export sales to select markets.
• Cost structure drivers: raw materials and cold-chain logistics, manufacturing capacity utilization, regulatory compliance costs, and R&D investment.

• Market standing: Zhifei is a leading domestic vaccine maker with a broad portfolio and strong provincial-level distribution coverage, positioning it among China's top vaccine producers.
• Recent headwinds: The company experienced a material revenue contraction in 2024 and continued weakness in Q1 2025 driven by demand shifts, inventory adjustments, and receivables recovery issues.
• R&D commitment: R&D headcount and spend place Zhifei in the industry's upper tier - R&D expenditure has been roughly 10-12% of revenue in recent years and the team counts in the high hundreds to low thousands, supporting pipeline vaccines and next‑generation formulations.
• Operational focus: Management is prioritizing inventory reduction, accelerating collection of outstanding receivables, and optimizing working capital to reduce liquidity and liability risk.
• Strategic initiatives: investments in advanced production lines, expanded cold-chain logistics, strategic partnerships, and continued pipeline development to regain growth momentum.

• Inventory turnover and days sales outstanding (DSO) as measures of receivables recovery.
• Capacity utilization and batch release volumes to restore margin profile.
• R&D pipeline milestones and regulatory approvals to drive medium-term revenue recovery.